FDA Approves Freenome's SimpleScreen CRC Blood Test; Abbott to Commercialize
FRNM sits 23% above its 52-week low of $9.95 on elevated volume (3.5× avg).
Summary
Freenome's SimpleScreen CRC blood test won FDA approval, a major regulatory milestone for the early cancer detection company. Abbott will exclusively commercialize the test in the U.S., leveraging its existing Cologuard infrastructure. Freenome receives a $100 million milestone payment, a significant cash infusion for a company with a ~$116M market cap. The test showed 81.1% sensitivity for colorectal cancer and 90.4% specificity in a large trial, with Medicare coverage and expected ACS guideline inclusion supporting adoption. This approval validates Freenome's platform and opens a large market of up to 60 million unscreened Americans. Abbott's involvement adds commercial credibility and distribution scale.
At the time of this announcement, FRNM was trading at $12.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $115.9M. The 52-week trading range was $9.95 to $14.47. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.